Drug Profile
AZD 5904
Alternative Names: AZD-5904Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator AstraZeneca
- Developer AstraZeneca; Conduit Pharmaceuticals
- Class Male infertility therapies
- Mechanism of Action Peroxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Male infertility
- No development reported Chronic obstructive pulmonary disease; Insulin resistance; Multiple sclerosis; Unspecified
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease in United Kingdom
- 28 Oct 2023 No recent reports of development identified for phase-I development in Multiple-sclerosis in United Kingdom
- 18 Oct 2023 AZD 5904 licensed to Conduit Pharmaceuticals in USA prior to October 2023 (Conduit Pharmaceuticals website, October 2023)